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Introduction
Male breast cancer (MBC) is a rare disease and little is
known about its aetiology. However, female first-degree
relatives of MBC cases are at increased risk of breast
cancer [1–6], which suggests that there is an inherited
component to the disease. Several genes that are associ-
ated with a high lifetime risk of breast cancer in women
have been identified during the past decade. One of
these, BRCA2, has also been shown to confer a signifi-
cant risk of breast cancer in men, and a recent study
found the risk of breast cancer in male BRCA2 mutation
carriers from multiple case breast/ovarian cancer families
to be 80-fold higher than in the general population [7].
This equates to a 7% risk of breast cancer by age 80. The
CI = confidence interval; MBC = male breast cancer; PCR = polymerase chain reaction; SSCA/HA = single strand conformation analysis/hetero-
duplex analysis.
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Abstract
Background: The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC)
in the United Kingdom is not known, and the importance of these genes in the increased risk of female
breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear.
Methods: We have carried out a population-based study of 94 MBC cases collected in the UK. We
screened genomic DNA for mutations in BRCA1 and BRCA2 and used family history data from these
cases to calculate the risk of breast cancer to female relatives of MBC cases. We also estimated the
contribution of BRCA1 and BRCA2 to this risk.
Results: Nineteen cases (20%) reported a first-degree relative with breast cancer, of whom seven also
had an affected second-degree relative. The breast cancer risk in female first-degree relatives was 2.4
times (95% confidence interval [CI] = 1.4–4.0) the risk in the general population. No BRCA1 mutation
carriers were identified and five cases were found to carry a mutation in BRCA2. Allowing for a
mutation detection sensitivity frequency of 70%, the carrier frequency for BRCA2 mutations was 8%
(95% CI = 3–19). All the mutation carriers had a family history of breast, ovarian, prostate or
pancreatic cancer. However, BRCA2 accounted for only 15% of the excess familial risk of breast
cancer in female first-degree relatives.
Conclusion: These data suggest that other genes that confer an increased risk for both female and
male breast cancer have yet to be found.
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prevalence of BRCA2 mutations in MBC cases unse-
lected for family history has been estimated in several
studies from Europe and the United States [8–14]. The
estimated mutation carrier frequencies varied from 4% to
40%, but were higher in the three studies carried out in
populations in which founder mutations are known to
occur [9,12,13]. Two other studies have screened for the
BRCA2 founder mutation 6174delT in male breast cancer
cases of Jewish origin unselected for family history.
Struewing  et al. identified 15 mutation carriers in 100
cases [15] and Sverdlov et al. found no mutation carrier in
20 cases [16].
A putative association between BRCA1 and MBC is less
clear. MBC is known to occur in multiple breast/ovarian
cancer case families with mutations in BRCA1 [17], but a
study of 22 MBC families found strong evidence against
linkage to the BRCA1 locus [18]. The two studies of the
Jewish  BRCA2 founder mutation described above also
screened for the BRCA1 founder mutation 185delAG.
Sverdlov et al. identified no mutation carrier in 20 cases
[16] and Struewing et al. identified four mutation carriers
out of 110 cases [15]. However, in two other studies of
MBC in populations without common founder mutations,
no mutation carriers were identified in a total of 72 cases
[10,13]. Together, these data suggest that the MBC risk
associated with BRCA1 is, at best, very small.
The purpose of this study was to estimate the breast
cancer risks in women with a family history of male breast
cancer and to establish the prevalence of BRCA1 and
BRCA2 mutations in a male breast cancer cases series
from the UK.
Materials and methods
Cases were identified from an ongoing population-based
study of male breast cancer. All men diagnosed with
breast cancer in the areas served by the East Anglia, Trent
and West Midlands cancer registries who were alive on
31 December 1998 were eligible to take part, excluding
those whose general practitioner thought them unsuitable
for the study because of severe concurrent illness. Partici-
pants were asked to complete a detailed epidemiological
questionnaire, which includes details of a family history of
cancer, and to provide a blood sample for genetic analy-
sis. The study has approval from the Anglia and Oxford
multi-centre research ethics committee. One hundred and
sixty-five eligible patients were identified, of whom 137
have so far agreed to take part. The first 94 patients who
enrolled in the study were included in the current analysis.
Pedigree data from the 94 index cases were used to esti-
mate the risk of breast cancer associated with a family
history of breast cancer in a male first-degree relative. The
program PERSON YEARS [19] was used to calculate the
expected number of breast cancers in female first-degree
relatives based on age and period specific breast cancer
incidence rates. Individuals entered the at risk cohort on 1
January 1960 and were censored on diagnosis of cancer,
on death, or on the date the family history questionnaire
was completed. Relatives born before 1890 and those
who died or developed cancer before 1960 were
excluded because reported data for these individuals was
likely to be less reliable.
BRCA1 and BRCA2 mutation analysis was performed as
previously described [20]. The whole coding sequence,
including intron–exon boundaries, was screened using a
combination of single strand conformation analysis/
heteroduplex analysis (SSCA/HA) and direct fluorescent
sequencing. DNA from six patients could not be reliably
amplified by PCR and these were excluded from the results.
Results
The mean age of diagnosis of the cases was 67.3 years
(range 36–89 years). Forty-five cases reported a history of
cancer in at least one first-degree relative. Of these, 18
reported a history of breast cancer in a female first-degree
relative, and one reported a brother with breast cancer. In
8125 person years of observation of first-degree female
relatives 16 breast cancers were observed compared to
6.63 expected, which equates to a relative risk of 2.4
(95% CI = 1.4–4.0).
We considered deleterious mutations to be those that are
predicted to result in protein truncation (frameshift, splice
site and nonsense mutations), or those missense muta-
tions that have been previously shown to be disease asso-
ciated on the basis of their co-segregation with disease in
families. No disease-associated mutations were identified
in BRCA1. Five disease-associated variants were identi-
fied in BRCA2 (Table 1). These were all in the coding
region and are predicted to lead to a truncated protein,
and all but one (2192delC) has been previously reported
on the Breast Information Core database [21]. The mean
age at diagnosis in the mutation carriers was 58.8 years
(range 48–69 years), which was 9 years younger than in
non-mutation carriers (67.9 years, range 36–89 years).
The five mutation carriers all reported a family history of
cancer (Table 1). One had a single second-degree relative
affected with breast cancer, and the other four had at least
one first-degree relative affected with one of the cancers
thought to be associated with BRCA2 (breast, prostate or
pancreas). We also identified rare missense mutations of
unknown significance in five patients (Table 1) and several
common polymorphisms in both BRCA1 and BRCA2.
Discussion
Our estimate of the familial risk of breast cancer associ-
ated with a family history of male breast cancer is similar
to other published estimates. However, our estimate is
based on a reported family history of breast cancer thatPage 3 of 5
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was not independently confirmed. It is known that a family
history of breast cancer is generally accurately reported by
women [22], but it may be less accurate for men, for
whom some degree of under-reporting is likely. This may
result in an underestimate of the familial risk.
As with other studies, we found no BRCA1 mutation carri-
ers in our case series. The carrier frequency of BRCA2
mutations was 6% (95% CI = 2–13%), which is broadly
comparable with that of previous estimates, but likely to be
an underestimate of the true carrier frequency. For
example, some of the missense variants that we identified
may disrupt the protein structure substantially, but in the
absence of a good functional assay for BRCA1 or
BRCA2 these variants were not classified as disease
causing. In addition, the sensitivity of SSCP/HA is known
to be less than 100%, and for nonsense mutations may be
as low as 50%. Finally, large genomic rearrangements
which will not be identified by PCR-based mutation detec-
tion methods are known to occur in BRCA1 and BRCA2.
A study combining linkage and mutation data in multiple
case families has estimated the sensitivity of the most
commonly used mutation detection techniques for these
genes to be approximately 70% [23]. Based on this sensi-
tivity, the frequency of BRCA2 mutations in this series
could be as high as 8%. Survival bias may also affect the
estimate of carrier mutation frequency. The participants in
this study were prevalent cases and carrier frequency may
be either underestimated or overestimated if male breast
cancer associated with a BRCA1 or  BRCA2 mutation
carries a different prognosis from breast cancer in men
without a mutation. However, there are no published data
Available online http://breast-cancer-research.com/content/4/1/R2
Table 1
Details of rare gene variants
Family history (age at diagnosis)
Patient Gene Variant Effect Age* First-degree relatives Second-degree relatives
Protein truncating mutations
M0271 BRCA2 253delC Frameshift 48 None MGM Br(?age)
M0041 BRCA2 2192delC Frameshift 55 F Pa(74) PU Pa(42), 
PA Br(48), PA Pa(63)
M0040 BRCA2 5974delCT Frameshift 60 F Pr(61) None
M0293 BRCA2 7928delCT Frameshift 69 M Br(67) None
M0238 BRCA2 8474delAG Frameshift 62 F Pr + Ki(75) None
Missense variants of unknown significance
M0383 BRCA1 2640C > T R841W 63 None None
M0016 BRCA2 5972T > C T1915M 74 F HN(85), B Lu(50’s) None
M0021 BRCA2 5972T > C T1915M 72 None None
M0288 BRCA2 4486G > T D1420Y 55 M Br(77) None
*Age at diagnosis (years). F, father; M, mother; B, brother; MGM, maternal grandmother; PU, paternal uncle; PA, paternal aunt; Br, breast cancer;
HN, head and neck; Ki, kidney cancer; Lu, lung cancer; Pa, pancreatic cancer; Pr, prostate cancer.
Figure 1
Summary of the location of published mutations in BRCA2 identified in male breast cancer cases (red triangles, this study; purple triangles, other
published studies).on outcome in BRCA-associated MBC, and in women the
effect of BRCA status on outcome is not clear [24,25].
The risk of female breast and ovarian cancer is thought to
vary depending on the location of mutations throughout
the BRCA2 gene [7]. Mutations in a central portion of the
gene, referred to as the ovarian cancer cluster region, are
associated with either an increase in the risk of ovarian
cancer, a decrease in the risk of breast cancer, or a com-
bination of both, compared with mutations elsewhere in
the gene. Figure 1 shows the location of BRCA2 muta-
tions identified by this and other studies of male breast
cancer. This illustrates that there appears to be no cluster-
ing of mutations that would indicate a genotype–pheno-
type correlation analogous to that observed for female
breast and ovarian cancer.
Our data show that BRCA2 accounts for only a small pro-
portion of the excess familial risk of female breast cancer
associated with MBC. There were 9.37 excess cases of
breast cancer in female first-degree relatives (16 observed
– 6.63 expected), of which only one was accounted for by
BRCA2. Thus, allowing for a mutation detection sensitivity
of 70%, BRCA2 accounts for approximately 15% of the
excess risk.
Conclusion
The majority of male breast cancer is not accounted for by
BRCA1 and BRCA2, and these genes account for only
15% of the excess familial risk of breast cancer in female
first-degree relatives. This suggests that other genes that
confer an increased risk for both female and male breast
cancer have yet to be found.
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